acv1 shows efficacy in trial

JULY 29 2007

Conus peptides targeting pain via alpha9alpha10 nicotinic receptors

Vincler M, McIntosh JM. (2007) Targeting the alpha9alpha10 nicotinic acetylcholine receptor to treat severe pain. Expert Opin Ther Targets. 11: 891-897.
Wake Forest University Health Sciences, Department of Anesthesiology, Medical Center Blvd., Winston-Salem, NC 27157, USA.

Abstract: The alpha9alpha10 nicotinic acetylcholine receptors (nAChRs) are recognized for their function in the hair cells of the inner ear; transcripts for a9 and/or a10 subunits have also been identified in a diverse range of other tissues , including immune cells. The functioning of alpha9alpha10 nAChRs in these latter tissues is unknown. However, A RECENT SERIES OF STUDIES HAS PROVIDED EVIDENCE that blockade of the alpha9alpha10 nAChR CAN ALLEVIATE CHRONIC PAIN resulting from overt peripheral nerve injury or inflammation and increase the functional recovery of damaged neurons. Systemic administration of alpha9alpha10 antagonists produces an acute analgesia; REPEATED DAILY ADMINISTRATIONS PRODUCED SUSTAINED AND CUMULATIVE LEVELS OF ANALGESIA ACROSS 7 DAYS WITHOUT THE DEVELOPMENT OF TOLERANCE. Although the exact mechanism of action is unknown, antagonism of the alpha9alpha10 nAChRs reduces the number of immune cells present at the site of injury.
Keywords: ACV1, analgesia, conotoxin, neuropathic pain, RgIA, Vc1.1

IMO the recent set of studies refer to the clinical trials recently completed by MBP which were performed over a 7 day period with a one week washout period and these may be one of the expert opinions MBP are refering to in their latest report ,
MBPs annoucement may now be out sooner.